Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CNTY-101 CAR iNK cell therapy in refractory B cell-mediated autoimmune diseases
NCT06255028Phase 1Active, not recruiting
- Sponsor
- Century Therapeutics
- Start
- Feb 2025
- Primary completion
- Aug 2028
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of CNTY-101 in systemic lupus erythematosus (SLE), lupus nephritis (LN), idiopathic inflammatory myopathies (IIM) and 1 more (4 arms), sponsored by Century Therapeutics. Primary endpoints: Treatment-emergent Adverse Events at 29 days, Dose Limiting Toxicities at 28 days and 1 more. Started Feb 2025; status: active, not recruiting.
02
Drugs
CNTY-101
03
Conditions
systemic lupus erythematosus (SLE)lupus nephritis (LN)idiopathic inflammatory myopathies (IIM)diffuse cutaneous systemic sclerosis (dcSSc)
Beyond the preview
Go deeper on NCT06255028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06255028.